Part 6/7:
Although the stock’s growth has been somewhat restrained due to its limited current offerings and domestic market focus, the company is making strides. Rhythm Technologies plans to expand internationally and diversify its product capabilities to include other critical health metrics, which could dramatically expand its addressable market.
Currently trading at over $90, analysts are projecting a growth rate of about 19% for Rhythm Technologies, with an optimistic consensus price target around $107. Notably, an analyst at Canaccord Genuity recently raised the price target from an already bullish $125 to an astonishing $152, signaling strong confidence in the company's future prospects.